U.S. Appeals Court Says Bausch Can Block Alvogen From Copying Xifaxan Diarrhea Drug Until 2029
Portfolio Pulse from Benzinga Newsdesk
A U.S. Appeals Court has ruled in favor of Bausch Health Companies Inc. (BHC), allowing it to prevent Alvogen from producing a generic version of its Xifaxan diarrhea drug until 2029, according to Reuters.
April 11, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The court ruling in favor of Bausch Health Companies Inc. (BHC) to block Alvogen from copying its Xifaxan drug until 2029 is a significant win, protecting its revenue from this product for several more years.
The court's decision directly protects Bausch Health's revenue from Xifaxan, a key product in its portfolio, by preventing generic competition until 2029. This is likely to positively impact investor sentiment and the stock price in the short term, as it secures a significant revenue source.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100